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Abstract: Since it was first described by Kossard in 1994, frontal fibrosing alopecia (FFA) has 
been something of an enigma. The clinical heterogeneity of FFA, its apparent rarity, and 
investigators’ suboptimal access to phenotypically consistent patient cohorts, may all have 
had a negative impact on delineating disease pathogenesis. Moreover, there is a relative 
paucity of epidemiologic interventional and basic research studies, and there have been no 
advances in translational therapeutics, unlike for other inflammatory dermatoses, such as 
alopecia areata (AA). Dermatologists anecdotally describe an increasing incidence in FFA 
over the last decade, which has led to the notion that the disorder may be induced by 
unknown environmental triggers. On the other hand, segregation of FFA in some families 
lends support to an unexplored genetic element implicated in disease pathogenesis.  We 
herein review what is known about the pathobiology of FFA and formulate working 
hypotheses to advance insight into this intriguing hair disorder. 
 
Keywords: FFA; frontal fibrosing alopecia; LPP; lichen planopilaris; scarring; cicatricial 
alopecia 
 
Introduction 
Cicatricial or scarring alopecias, whether primary or secondary, are a therapeutically 
challenging problem in clinical practice. Primary cicatricial alopecias (PCA) represent a rather 
diverse group of inflammatory disorders, where the common denominator, in pathologic 
terms, is the irreversible destruction of hair follicles. Frontal Fibrosing Alopecia (FFA) is a 
recently described, predominantly postmenopausal, primary lymphocytic cicatricial alopecia 
(1) that has been thought to be a variant of lichen planopilaris (LPP) (2). Clinically, the 
disorder involves the frontotemporal hairline with perifollicular erythema, follicular 
hyperkeratosis and scarring with evident hairline recession, although clinical signs of 
inflammation are not always evident (3). Eyebrow loss is recorded in 50%-83% of cases (3–5) 
but body hair loss has been less commonly reported, as has eyelash volume loss (0%-77%) 
(5-7). The histology of FFA (Fig 1) is similar to that of classic (multifocal) LPP, with the early 
active stages showing a perifollicular lichenoid inflammatory infiltrate involving the isthmus 
and infundibulum; later stages are characterized by perifollicular fibrosis with follicular 
dropout and follicular scars replacing the pilosebaceous units (2, 8). The inflammatory focal 
point in FFA is the bulge area of the hair follicle (HF) in contrast to alopecia areata (AA), 
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where the bulb at the lower third of the HF is at the epicentre (9, 10). The identical 
histological appearance accounts for the widespread acceptance of FFA as clinical sub-
variant of (follicular) lichen planus (11).  
 
Dividing PCAs histologically into lymphocytic, neutrophilic and mixed, has guided clinical 
classification but microscopic characterisation may not reflect upstream differences in 
pathogenesis. Neither do the histological similarities reflect clinical overlap: the classic 
pattern of LPP behaves differently clinically and epidemiologically from its rather distinct 
subvariant FFA: the latter has a striking clinical pattern of ear-to-ear scarring hair loss, often 
with eyebrow and body hair involvement and much commoner in postmenopausal women 
(12, 13). Only rarely does FFA affect men whereas LPP does not show a gender or older age 
predilection. Of note, pediatric cases of LPP have also been reported, whereas FFA is 
unheard of in the pediatric population (14). 
 
The exact pathogenesis of FFA remains unknown. Its postmenopausal occurrence led to the 
speculation of a hormone-related triggering mechanism. Moreover, 5-alpha reductase 
inhibitors have been reportedly used with some success, although it has been argued that 
the beneficial effect of these may be on any concomitant androgenetic element of hair loss, 
while the overall evidence-basis for this claim remains poor (12, 15). There have been 
familial cases of FFA reported in the literature (16–19) but robust genetic analysis of the 
condition has not been undertaken to date.  
 
The case for a genetic basis underlying FFA and the role of the environment 
Genetic exploration has been instrumental in revealing molecular pathways underlying 
alopecic variants, such as Marie-Unna hypotrichosis (20) and alopecia areata (AA) (21), 
among other cutaneous disorders. It would therefore be prudent to consider the research 
question of whether there is genetic basis to be explored and, if so, what method would be 
more appropriate to employ in doing so.  
The notion that FFA is underlain by a genetic element is supported primarily by evidence of 
disease segregation in first-degree relatives. We and others (16–19) have reported familial 
cases of FFA, where the observed inheritance is in keeping with an autosomal dominant 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
mode with incomplete penetrance, lending support to the hypothesis that the trait in 
question may be Mendelian. The exceptionally rare incidence of the disorder would also be 
in keeping with the hypothesis that FFA is caused by rare alleles of large effect size. Twin 
studies can be insightful in discerning whether a trait is strongly genetic and we have 
undertaken a search in the UK via our network of collaborating clinicians and Twins UK: 3 
pairs of monozygotic (MZ) twins affected by FFA have been identified, 2 of which are 
concordant and 1 discordant (67% concordance vs 33% discordance) in a cohort of just over 
12,000 individuals. It should be emphasized that the rare overall incidence of FFA and the 
small number of twin pairs identified (N=3) warrant caution in interpreting the above 
observation. Moreover, even strongly genetic conditions, such as systemic lupus 
erythematosus (SLE), are characterized by higher discordance among MZ twins (22), thereby 
supporting the suggestion that epigenetics may play a profound role in FFA pathogenesis in 
addition to genetic predisposition. Nevertheless, case-studying of MZ cases could be 
insightful when undertaken with robust research methods.  
 
On the other hand, the apparent recent increase in the overall incidence of FFA has sparked 
interest in ‘environmental’ triggers (23). The late onset of FFA could imply lower genetic 
causality, although there are plenty of disorders, which are characterized by late life onset 
and yet which are known to be genetically predisposed, such as systemic lupus 
erythematosus (SLE) (24) and hidradenitis suppurativa (HS) (25). It is worth noting that, 
despite the later-life manifestations of the classic frontal fibrosing pattern of hair loss, 
individuals affected by FFA report, in our experience, lifelong body hair loss, predating 
eyebrow and scalp involvement. This diffuse and perhaps unrecognized long-term hair loss 
would also be in keeping with germline predisposition, enhanced by a more complex 
interplay of possible hormonal factors postmenopause.  
 
Parallels between FFA and AA 
The concept of immune-privileged anatomical sites has been well-established since 
Medawar’s experiments, which demonstrated that allogeneic skin grafts are not subjected 
to immunological rejection when transplanted into certain sites, such as the eye or brain 
(26). Within the skin, the hair follicle (HF) is a site of relative immune privilege (IP), which 
serves as a protective strategy against autoimmune injury. Protection is achieved by 
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downregulation of major histocompatibility complex (MHC) class I and β2 microglobulin in 
the bulb and bulge of the hair follicle epithelium, besides an augmented expression of a local 
immunosuppressive milieu. In physiological terms, the exact role of the HF IP remains 
somewhat unclear, although proposed theories have included the possibility of the crucial 
evolutionary benefit of ensuring mammals such as polar bears maintained their hair (27–33). 
Relative IP loss in anagen hair follicular epithelium is postulated to underlie the organ-
specific auto-immune disorder AA, where loss of relative IP leads to ectopic MHC class I 
expression and, as yet elusive, autoantigens trigger a CD8+T cell-mediated inflammatory 
process, microscopically seen as the classic peribulbar ‘swarm of bees’ (Fig 2) (34–36).  
 
The IP-privileged HF bulge is home to epithelial hair follicle stem cells (37). The crucial role of 
epithelial hair follicle stem cells (eHFSC) in the pathobiology of PCA is well established: 
destruction of the bulge is detrimental to the HF’s regenerative ability and is seen in 
permanent, scarring types of alopecia (38, 39). Harries et al. studied how proinflammatory 
events influence eHFSC integrity and postulated that LPP (and variant FFA) represents a T-
cell dependent autoimmune disorder, underlain by IFNγ–Induced IP collapse at the level of 
the bulge (40). IP collapse was evidenced by reduced expression of the IP guardians TGFβ2 
and CD200 and enhanced expression of the normally locally down-regulated presence of 
MHC class I/II and β2 microglobulin, which are thought to limit autoantigen presentation 
(41). In other words, LPP and variant FFA were postulated to mirror the autoimmune 
process underlying AA with the difference that IP in AA is centred at the deeper but less 
catastrophic potential bulb, as opposed to the critical stem cell niche and anatomically more 
superficial bulge. The observed features were only found to characterise lesional areas of 
scalp skin in individuals affected by LPP, whereas the previously proposed crucial role of 
defective PPARγ signalling, which Karnik and colleagues (42) found to underlie both lesional 
and non-lesional scalp skin, could not satisfactorily explain the pattern of patchy 
involvement in LPP. On the other hand, as Harries et al. pointed out, that study did not allow 
one to conclude whether IFNγ production preceded CD8+ T cell infiltration at the bulge level 
or whether elusive factors attract T cells, which would subsequently secrete IFNγ, thereby 
causing IP collapse (41).  
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Genetic determinants in the pathogenesis of AA were revealed with the help of the genome-
wide association study led by Christiano and colleagues: a region of strong association within 
the novel ULBP gene cluster on chromosome 6q25.1 was identified, which encodes 
activating ligands of the natural killer cell receptor NKG2D (21). When probed, it was 
demonstrated that ULBP3 was expressed in lesional scalp and upregulated in the HF dermal 
sheath during active disease stages (21). If we consider LPP and variant FFA to be 
immunologically analogous to a bulge-affecting AA-like process, it might be anticipated that 
the causative weak link in LPP and variant FFA could be reminiscent to ULBP3: an 
overexpressed ‘danger signal’ or a defective ‘gate-keeper’ at the level of the bulge, 
responsive to stressors that might impose a breach of the integrity of the follicular unit. Such 
a locus could be explored using an investigational genomic approach. 
 
Can we get clues about FFA from other fibrotic disorders? 
Fibrotic disorders comprise a multitude of clinical entities, ranging from widespread 
systemic sclerosis (43, 44), multifocal fibrosclerosis (45, 46), sclerodermatous graft-
versus-host disease (47) and nephrogenic systemic fibrosis (48, 49) to more organ-
specific disorders such as cutaneous, pulmonary, hepatic, and renal fibrosis (7, 50–
52). Whether reactive or reparative, these fibrotic disorders are defined by excessive 
fibrous connective tissue and aberrant and excessive deposition of extracellular 
matrix (ECM) in involved tissues. Enhanced expression of genes encoding matrix 
proteins is a common finding in many of these conditions, where the resulting 
fibrosis disrupts normal architecture, ultimately leading to organ dysfunction and 
failure (53–55). A common feature is a dense population of activated fibroblasts or 
myofibroblasts, which are largely responsible for the hyper-fibrotic response by 
promoting the production of fibrillar type I and type III collagens and reducing 
expression of genes encoding extracellular matrix (ECM)–degradative enzymes (56–
59). Although the exact origins of the mesenchymal cells leading the aberrant 
collagen and ECM protein production has not been entirely elucidated, resident 
fibroblasts, bone-marrow derived fibrocytes, as well as endothelial and epithelial 
cells undergoing epithelial-to-mesenchymal transition (EMT) are important players in 
the process (60).  
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One immunohistochemical marker of EMT is Snail1 (61) which is expressed in the 
fibrotic dermis of individuals affected by FFA (62), indicating that profibrotic cells 
may be derived at least in part by of EMT, where molecules such as TGFβ could be 
key. This makes one consider targeting such molecular regulators (or EMT-related 
miRNA) to arrest or reverse the fibrotic process, whether in skin, liver, lungs or 
kidneys. 
 
Hormones and trauma: true culprits or mere helpers and enemies?  
FFA is known to almost exclusively affect women of postmenopausal age (1, 2). Of the 150 
cases that currently are under our care, the vast majority developed the disorder after 
menopause, whereas the few younger female patients had iatrogenic, syndromic or 
biochemical estrogen decline prior to developing FFA (namely ovarectomy, Turner’s 
syndrome or early menopause). Of course, disease chronicity is known to be associated with 
excessive fibrous tissue deposition, altered tissue architecture, and organ dysfunction and 
fibrosis per se increases in all organs with aging (63, 64). Estrogen has been found to exert 
antifibrotic effects in vivo (65) and act as potent immunomodulator by suppressing central, 
innate and adaptive immunity in certain cell types (66), although its effects are known to be 
variable (67). Does menopause simply coincide with the profibrotic processes of aging or 
does the menopausal estrogen decline cause unfavourable immunomodulation, thereby 
allowing a lifelong condition to declare itself and come to the fore? The latter may be in 
keeping with our observation that other body regions in people with FFA are hairless from a 
much younger age, thus predating the more intense manifestations of the disorder that 
occur much later. Male FFA may also be consistent with the above hypothesis: serum 
testosterone levels are known to decrease with ageing, as does its aromatase-induced 
conversion to estrogen (68, 69). In either scenario, hormone replacement following 
realisation of disease activity would not possibly be capable to reverse the underlying 
process of immune privilege collapse and autoantigen driven lymphocytic attack. 
The observation that hair transplantation and face-lift surgery re-activates the disease 
process (70–72) may also be in keeping with the above hypothesis: the disordered immune-
mediated collapse of the hair-follicle’s privileged integrity may well leave local factors, such 
as memory T-cells in skin stroma. In line with this, when apparently normal autologous hair 
follicles are transplanted to a region previously involved with FFA, subjects can develop the 
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histological hallmarks of the disease (73, 74). Any traumatic or inflammatory insult or merely 
implanting more antigens by transplanting hairs in that stroma would be germane to 
stepping into an active but quiet minefield before the ensuing catastrophe becomes 
macroscopically and clinically noticeable.  
 
Are there potential diagnostic markers or disease biomarkers for FFA? 
MicroRNAs (miRNAs) are relatively recently discovered small, endogenous, non-coding 
ribonucleic acid molecules (RNAs) that affect various cellular processes underlying health 
and disease by exerting target gene expression regulatory functions (75, 76). Recent years 
have seen miRNAs emerging as key determinants of organ phenotypes and potential 
candidates of prognostic, diagnostic and therapeutic interest in numerous disease processes 
(77–81). Aberrant expression or function of miRNAs has been implicated in a broad 
spectrum of human disorders, such as several types of malignancy, neurodegenerative, 
infectious, metabolic, chronic inflammatory, fibrotic and autoimmune diseases (82–89) and 
this has led to widespread attention to miRNAomics.    
It has recently been discovered that miRNAs can be detected in plasma and serum, where 
they circulate in a stable form (90–92) mostly because of their encapsulation in serum 
microvesicles or exosomes (93). There is relative paucity of microRNAomic investigations in 
cutaneous pathophysiology with the notable exception of psoriasis (94) rendering the 
prospect of exploring their potential usefulness in FFA and other related alopecic disorders a 
very attractive one and we are pursuing. 
 
Proposed strategies for advancing insights into FFA 
In order to dissect the molecular etiopathogenesis of FFA, a genomic investigation would 
need to explore if there is a genetic component underlying any observed heritability (Table 
1). Whether rare coding alleles of large effect size determine FFA would best be addressed 
via deep sequencing affected familial cases. By studying related, highly clinically consistent 
individuals it is anticipated that the shared phenotype is caused by shared genetic variation, 
an approach that circumnavigates the problem of heterogeneity. Nevertheless, the vast 
majority of cases are sporadic and it would be important to explore whether common 
genetic variation or more complex pathways predispose to disease: a genome-wide 
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association study may be the best research tool in delineating underlying pathways, while 
also examining gene-environment interactions, an approach we are currently recruiting for. 
The overall rare incidence argues against an environmental etiology as the sole pathogenic 
determinant, although carefully designed observational studies could examine this notion, 
ideally followed by epigenetic exploration. 
 
Identifying a refined genetic or protein micro-entity as a biomarker would be indispensable 
to disease prognostication and could help optimise therapeutic strategies: circulating 
microRNA and metabolomic profiling may also be an appropriate approach but may be 
challenging to validate, given the slowly progressive nature of FFA requiring a prolonged and 
carefully controlled study.  
 
Appreciation of the normal scalp cutaneous cell demographics and architecture and regional 
gene expression differences could potentially help understand the pattern of disease: 
appropriate transcriptomic analysis and suitable functional organ and in vivo models would 
be essential and complementary to genomic investigation. Sine qua non to molecular 
delineation is the necessity for deep phenotyping and understanding the clinical character of 
FFA. To this end, is it time for Cicatricial Alopecia Registry UK (CAR-UK) or, why not, CAR-EU? 
We have set the foundation stone by establishing a UK-wide research network via the NIHR 
UK Rare Disease Research Consortium Agreement and look forward to gaining new 
momentum in the important but thus far understudied area of rare alopecic, scarring and 
lichenoid dermatoses. 
 
Acknowledgements 
The authors wish to thank Twins UK, the NIHR UK Rare Genetic Disease Research 
Consortium and the Department of Health for allowing access to their database; 
their help with establishing a UK-wide network of participating NHS sites for patient 
recruitment; and for funding this initiative, respectively. 
 
Author contributions 
CT, DAF, CMS, MAS and JAM take full responsibility of the contents of the 
manuscript. CT and JAM wrote the paper. CMS contributed to Fig 1 and Fig 2. CT, 
DAF, CMS, MAS and JAM provided critical revision of the manuscript.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Author contributions 
Jimenez, Poblet and Izeta take full responsibility of the contents of the manuscript. 
Jimenez and Izeta wrote the paper. Poblet provided Fig. 1 and Izeta provided Fig. 2. 
Critical revision of the manuscript for important intellectual content: Jimenez, Poblet 
and Izeta. Administrative support: Jimenez. 
 
Funding sources 
CT holds a National Institute for Health Research (NIHR) Fellowship and an honorary 
contract with the National Health Service (NHS). DAF and CMS are employed by the NHS. 
MAS and JAM are employed by King's College London and JAM also holds an honorary NHS 
contract with the host organization (Guy's and St Thomas' Hospitals NHS Foundation Trust). 
 
Conflicts of interest 
None declared 
 
REFERENCES 
1. Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a 
pattern distribution. Arch Dermatol 1994; 130:770-4 
2. Kossard S, Lee MS, Wilkinson B. Postmenopausal frontal fibrosing alopecia: a 
variant of lichen planopilaris. J Am Acad Dermatol 1997; 36: 59-66 
3. Tan KT. Messenger AG. Frontal fibrosing alopecia: clinical presentation and 
prognosis. Br J Dermatol 2009; 160: 75-9 
4. Moreno-Ramirez D, Camacho Martinez F. Frontal fibrosing alopecia: a survey 
in 16 patients. J Eur Acad Dermatol Venereol 2005; 19: 700-5 
5. Samrao A, Chew AL, Price V. Frontal fibrosing alopecia: a clinical review of 36 
patients. Br J Dermatol 2010; 163: 1296-300 
6. Camacho Martinez F, Garcia-Hernandez MJ, Mazuecos Blanca J. Post-
menopausal frontal fibrosing alopecia. Br J Dermatol 1999; 140: 1181-2 
7. Chew AL, Bashir SJ, Wain EM, et al. Expanding the spectrum of frontal 
fibrosing alopecia: a unifying concept. J Am Acad Dermatol 2010; 63: 653-60 
8. Vañó-Galván S, Molina-Ruiz AM, Serrano-Falcón C, et al. Frontal fibrosing 
alopecia: a multicenter review of 355 patients. J Am Acad Dermatol 2014; 70: 
670-8 
9. Eudy G, Solomon AR. The histopathology of noncicatricial alopecia. Semin. 
Cutan. Med Surg 2006; 25: 35–40. 
10. Sperling LC. Alopecia areata. In An atlas of hair pathology with clinical 
correlations. New York, NY: The Parthenon Publishing Group, 2003; 63–78. 
11. Poblet E, Jimenez F, Pascual A, Pique E. Frontal fibrosing alopecia versus 
lichen planopilaris: a clinicopathological study. Int J Dermatol 2006; 45: 375-
80 
12. MacDonald A, Clark C, Holmes S. Frontal fibrosing alopecia: a review of 60 
cases. J Am Acad Dermatol 2012; 67: 955-61 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
13. Griffin LL, Michaelides C, Griffiths CE, et al. Primary cicatricial alopecias: a 
U.K. survey. Br J Dermatol 2012; 167: 694-7 
14. Pandhi D, Singal A, Bhattacharya SN. Lichen planus in childhood: a series of 
316 patients. Pediatr Dermatol 2014; 31: 59-67 
15. Holmes S, MacDonald A. Frontal fibrosing alopecia. J Am Acad Dermatol 
2014; 71: 593-4 
16. Dlova N, Goh CL, Tosti A. Familial frontal fibrosing alopecia. Br J Dermatol 
2013; 168: 220-2  
17. Junqueira Ribeiro Pereira AF, Vincenzi C, Tosti A. Frontal fibrosing alopecia in 
two sisters. Br J Dermatol 2010; 162: 1154-5 
18. Navarro-Belmonte MR, Navarro-López V, Ramírez-Boscà A, et al. Case series 
of familial frontal fibrosing alopecia and a review of the literature. J Cosmet 
Dermatol 2015; 14: 64-9 
19. Tziotzios C, Fenton DA, Stefanato CM, McGrath JA. Familial frontal fibrosing 
alopecia. J Am Acad Dermatol 2015; 73: e37 
20. Wen Y, Liu Y, Xu Y, et al. Loss-of-function mutations of an inhibitory upstream 
ORF in the human hairless transcript cause Marie Unna hereditary 
hypotrichosis. Nat Genet 2009; 41: 228-33 
21. Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in 
alopecia areata implicates both innate and adaptive immunity. Nature 2010; 
466: 113-8 
22. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin 
concordance in systemic lupus erythematosus. Arthritis Rheum  1992; 35: 
311-8 
23. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=13382 
(Accessed November 2015) 
24. Alarcón-Riquelme ME, Ziegler JT, Molineros J, et al. GWAS in an Amerindian 
ancestry population reveals novel systemic lupus erythematosus risk loci and 
the role of European admixture. Arthritis Rheumatol 2015; Nov 25 
25. Pink AE, Simpson MA, Desai N, et al. Mutations in the γ-secretase genes 
NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa 
(acne inversa). J Invest Dermatol 2012; 132: 2459-61 
26. Medawar P. Immunity to homologous grafted skin III. The fate of skin 
homografts transplanted to the brain, to subcutaneous tissue, and to the 
anterior chamber of the eye. Br J Exp Pathol 1948; 129: 58-69 
27. Paus R, Bertolini M. The role of hair follicle immune privilege collapse in 
alopecia areata: status and perspective. J Invest Dermatol Symp Proc 2013; 
16: S25-7 
28. Cotsarelis G, Millar SE. Towards a molecular understanding of hair loss and its 
treatment. Trends Mol Med 2001; 7: 293-301 
29. Christoph T, Muller-Rover S, Audring H, et al. The human hair follicle immune 
system: cellular composition and immune privilege. Br J Dermatol 2000; 142: 
862-873 
30. Ito T, Ito N, Bettermann A, et al. Collapse and restoration of MHS class-I-
dependent immune privilege: exploiting the human hair follicle as a model. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Am J Pathol 2004; 164: 623-634 
31. Ito T, Ito N, Saatoff M, et al. Maintenance of hair follicle privilege is linked to 
prevention of NK cell attack. J Invest Dermatol 2008; 128: 1196-1206 
32. Paus R, Nickoloff BJ, Ito T. A ‘hairy’ privilege. Trends Immunol 2005; 26: 32-40 
33. Breitkopf T, Lo BK, Leung G, et al. Somatostatin expression in human hair 
follicles and its potential role in immune privilege. J Invest Dermatol 2013; 
133: 1722-1730 
34. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012; 366: 1515-
1525 
35. Kang H, Wu WY, Lo BK, et al. Hair follicles from alopecia areata patients 
exhibit alterations in immune privilege-associated gene expression in 
advance of hair loss. J Invest Dermatol 2010; 130: 2677-2680 
36. Harries MJ, Sun J, Paus R, et al. Management of alopecia areata. Br Med J 
2010; 341: c3671 
37. Meyer KC, Klatte JE, Dinh HV, et al. Evidence that the bulge region is a site of 
relative immune privilege in human hair follicles. Br J Dermatol 2008; 159: 
1077-1085 
38. Harries MJ, Paus R. The pathogenesis of primary cicatricial alopecias. Am J 
Pathol 2010; 177: 2152-2162 
39. Ohyama M. Primary cicatricial alopecia: recent advances in understanding 
and management. J Dermatol 2012; 39: 18-26 
40. Harries MJ, Meyer K, Chaudhry I, et al. Lichen planopilaris is characterised by 
immune privilege collapse of the hair follicle’s epithelial stem cell niche. J 
Pathol 2013; 231: 236-47 
41. Karnik P, Tekeste Z, McCormick TS, et al. Hair follicle stem cell-specific PPARγ 
deletion causes scarring alopecia. J Invest Dermatol 2009; 129: 1243-1257 
42. Varga J, Abraham D. Systemic sclerosis: a prototypic multi-system fibrotic 
disorder. J Clin Invest 2007; 117: 557-567 
43. Denton CP, Black CM. Scleroderma: clinical and pathological advances. Best 
Pract Res Clin Rheumatol 2004; 18: 271-290 
44. Gleeson MH, Taylor S, Dowling RH. Multifocal fibrosclerosis. Proc Roy Soc 
Med 1970; 63: 1309-1311 
45. Neild GH, Rodriguez-Justo M, Wall C, Connolly JO. Hyper-IgG4 disease: report 
and characterization of a new disease. BMC Med 2006; 4: 23 
46. White J.M., Creamer D., du Vivier A.W., Pagliuca A., Ho A.Y., Devereux S., 
Salisbury J.R., Mufti G.J. Scleroderma graft-versus-host disease: clinical 
spectrum and therapeutic challenges. Br J Dermatol.2007;156:1032–1038 
47. Cowper SE. Nephrogenic systemic fibrosis: an overview. J AM Coll 
Radiol 2008; 5: 23-28 
48. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of 
nephrogenic fibrosing dermopathy and review of the literature. Semin 
Arthritis Rheum 2006; 35: 238-249 
49. Noble PW. Idiopathic pulmonary fibrosis: natural history and prognosis. Clin 
Chest Med 2006; 27: S11–S16  
50. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218 
51. Schnaper HW, Kopp JB. Renal fibrosis. Front Biosci 2003; 8: e68-e86 
52. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
cellular and molecular mechanisms and novel therapies.  Ann Intern 
Med 2010; 152: 159-166 
53. Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic 
sclerosis: emerging concepts and implications for targeted 
therapy. Autoimmun Rev 2011; 10: 267-275 
54. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 
199-210 
55. Krieg T, Abraham ., Lafyatis R. Fibrosis in connective tissue disease: the role 
of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res 
Ther 2007; 9: S4 
56. Neilson EG. Mechanisms of disease: fibroblasts: a new look at an old 
problem. Nat Clin Pract Nephrol2006; 2: 101-108 
57. Abraham DJ, Eckes B, Rajkumar V, Krieg T. New developments in fibroblast 
and myofibroblast biology: implications for fibrosis and scleroderma. Curr 
Rheumatol Rep 2007; 9: 136-143 
58. McAnulty RJ. Fibroblasts and myofibroblasts: their source, function and role 
in disease. Int J Biochem Cell Biol 2007; 39: 666-671 
59. Piera-Velazquez S, Li Z, and  Jimenez SA. Role of Endothelial-Mesenchymal 
Transition (EndoMT) in the Pathogenesis of Fibrotic Disorders. Am J Pathol 
2011; 179: 1074-1080. 
60. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal 
transitions in development and disease. Cell 2009; 139:871-90 
61. Nakamura M, Tokura Y Expression of Snail1 in the fibrotic dermis of 
postmenopausal frontal fibrosing alopecia: possible involvement of an 
epithelial-mesenchymal transition and a review of the Japanese patients. Br J 
Dermatol 2010; 162: 1152-4 
62. Nakanuma Y, Sato Y, Kiktao A. Pathology and pathogenesis of portal 
venopathy in idiopathic portal hypertension: hints from systemic 
sclerosis. Hepatol Res 2009; 39: 1023-1031 
63. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 
199-210 
64. Kapetanaki MG, Mora AL, Rojas M. Influence of age on wound healing and 
fibrosis. J Pathol 2013; 229: 310-322 
65. Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on 
dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999; 
29: 719-727 
66. Nadkarni S, McArthur S. Oestrogen and immunomodulation: new 
mechanisms that impact on peripheral and central immunity. Curr Opin 
Pharmacol 2013; 13: 576-81 
67. Walker SE. Estrogen and autoimmune disease. Clin Rev Allergy 
Immunol 2011; 40: 60-5 
68. Pirke KM, Sintermann R, Vogt HJ. Testosterone and testosterone precursors 
in the spermatic vein and in the testicular tissue of old men. Reduced oxygen 
supply may explain the relative increase of testicular progesterone and 17 
alpha-hydroxyprogesterone content and production in old age. Gerontology 
1980; 26: 221-30 
69. Feldman HA et al. Age trends in the level of serum testosterone and other 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
hormones in middle-aged men: longitudinal results from the Massachusetts 
male aging study. J Clin Endocrinol Metab 2002; 87: 589-98 
70. Crisóstomo MR, Crisóstomo MC, Crisóstomo MG, et al. Hair loss due to lichen 
planopilaris after hair transplantation: a report of two cases and a literature 
review. An Bras Dermatol 2011; 86: 359-62 
71. Chiang YZ, Tosti A, Chaudhry IH, et al. Br J Dermatol 2012; 166: 666-370 
72. Donovan J. Lichen planopilaris after hair transplantation: report of 17 cases. 
Dermatol Surg 2012; 38: 1998-2000 
73. Nusbaum BP, Nusbaum AG. Frontal fibrosing alopecia in a man: results of follicular 
unit test grafting. Dermatol Surg 2010; 36): 959-962 
74. Jiménez F, Poblet E. Is hair transplantation indicated in frontal fibrosing alopecia? 
The results of test grafting in three patients. Dermatol Surg 2013; 39: 1115-8 
75. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with 
probable regulatory roles in Caenorhabditis elegans. Science 2001; 294: 858-862.  
76. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and 
tumorigenesis. Br J Cancer 2006; 94: 776–80 
77. Galasso M, Elena Sana M, Volinia S. Non-coding RNAs: a key to future personalized 
molecular therapy? Genome Med 2010; 2: 12 
78. Williams AH, Liu N, van Rooij E, Olson EN. MicroRNA control of muscle development 
and disease. Curr Opin Cell Biol 2009; 21: 461-9.  
79. Wu X, Piper-Hunter MG, Crawford M, et al. MicroRNAs in the pathogenesis of lung 
cancer. J Thorac Oncol 2009; 4:1028-34  
80. Yang BF, Lu YJ, Wang ZG. MicroRNAs and apoptosis: implications in the molecular 
therapy of human disease. Clin Exp Pharmacol Physiol 2009; 36: 951-60.  
81. Zorio E, Medina P, Rueda J, et al. Insights into the role of microRNAs in cardiac 
diseases: from biological signalling to therapeutic targets. Cardiovasc Hematol 
Agents Med Chem 2009; 7: 82-90 
82. Zhang B, Farwell MA. microRNAs: a new emerging class of players for disease 
diagnostics and gene therapy. J Cell Mol Med 2008; 12: 3-21 
83. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor 
suppressors. Dev Biol 2007; 302: 1–12 
84. Krutzfeldt J, Stoffel M. MicroRNAs: a new class of regulatory genes affecting 
metabolism. Cell Metab 2006; 4: 9-12 
85. Eacker SM, Dawson TM, Dawson VL. Understanding microRNAs in 
neurodegeneration. Nat Rev Neurosci 2009; 10: 837-841 
86. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Autoimmun 2009; 32: 189-194 
87. Chung AC, Lan HY. MicroRNAs in renal fibrosis. Front Physiol 2015; 6: 50 
88. Patel V, Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 2012; 
21: 410-6 
89. Yang G, Yang L, Wang W, et al. Discovery and validation of 
extracellular/circulating microRNAs during idiopathic pulmonary fibrosis 
disease progression. Gene 2015; 562: 138-44 
90. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers 
PLoS One 2008; 3: e3148 
91. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: A novel class of 
biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006 
92. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based 
markers for cancer detection Proc Natl Acad Sci USA 2008; 105:10513–10518 
93. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human 
peripheral blood microvesicles. PLoS One 2008; e3694: 3 
94. Hawkes JE, Nguyen GH, Fujita M, et al. microRNAs in Psoriasis. J Invest 
Dermatol 2016; 136: 365-71 
 
Table 1. A summary of research questions and potential strategies for working and alternate 
hypothesis 
 
Hypothesis Proposed Experimental Strategy  
1. Familial FFA is determined by rare, large 
effect size, coding alleles 
Whole-exome sequencing 
2. Sporadic FFA is due to common genetic 
variation 
Genome-wide association study (GWAS) 
3. Sporadic FFA is due to environmental 
factors 
Observational/cross-sectional study; 
Epigenome-wide association study (EWAS) 
4. FFA is a complex trait attributed to 
interplay between genetic and environmental 
contribution 
Gene-environment interaction across the 
genome via GWAS and multiple testing 
correction for each interaction 
5. The pattern of FFA may be explained by 
regional differences conferring immune 
privilege advantage for follicular units in 
certain areas of the scalp 
Characterization of normal skin for 
cutaneous cell populations 
immunohistochemically and for gene and 
protein expression via RNA sequencing and 
proteomic analysis 
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FIGURE LEGENDS 
Figure 1: Frontal fibrosing alopecia: Scalp with frontal hairline recession involving the 
temporal areas bilaterally (A), as well as the eyebrows (B). Histopathology shows 
perifollicular fibrosis with a moderately dense perifollicular lymphoid cell infiltrate involving 
several hair follicles X40, (C). Detail showing the different phases of the scarring process in 
different hair follicles leading to hair loss, 100X (D). 
Figure 2: Alopecia areata: Retroauricular scalp with a patch of non-scarring alopecia with 
exclamation hairs (A), which are best appreciated with trichoscopy (B).  Histopathology 
shows an increased number of telogen hair follicles with peribulbar lymphoid cell infiltrate 
X40(C). Detail of the peribulbar lymphoid cell infiltrate ‘swarm of bees’ X400  (D). 
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